- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02452905
Finding Better Treatment of Bronchiolitis: A Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments
A Phase II Double-blind Randomised, Placebo-controlled Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nitazoxanide (NTZ) is a novel anti-infective medication that is licenced for use in the United States (US), including in children and infants for treating some infections. It is in the thiazolide class of antimicrobials and has been shown to have in vitro and/or clinical activity against a broad spectrum of pathogens, including a range of viruses, parasites and bacteria.
This study will determine whether NTZ is an effective empirical treatment for bronchiolitis. It will also help us to understand what effect NTZ has on the amount of virus present and how viral load changes over the course of the disease. If this study shows that NTZ is a useful treatment, then a larger study will be conducted enrolling infants that present to primary care facilities.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Western Australia
-
Perth, Western Australia, Australia, 6008
- Telethon Kids Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged greater than or equal to 1 month to less than or equal to 12 months
- Diagnosed with bronchiolitis by the assessing doctor
- Parent/legally responsible carer has provided informed consent for their infant/child to participate in the study
- Parent/legally responsible carer able and willing to comply with the requirements of the protocol
- Parent/legally responsible carer willing to attend a study follow up visit on study day 3 if their infant/child has previously been discharged from hospital
- Parent/legally responsible carer willing to allow other parties involved in the treatment of his or her child (including the general practitioner, paediatrician, hospital medical and nursing staff, community clinic staff) to be notified of participation in the trial
- Infants and children whose parent is willing to allow the study team to obtain an interim medical history from the participants electronic medical records (including immunisation records) and/or from the participants general practitioner or other medical professional for the period from enrolment to study day 180
Exclusion Criteria:
- Presence of symptoms of bronchiolitis (breathing difficulty, difficulty feeding, cough, poor feeding) for greater than or equal to 48 hours at the time of enrolment
- Born at gestational age of less than 32 weeks
- Has a history of any condition associated with risk of severe bronchiolitis including (significant cardiovascular disease, including congenital heart disease, significant respiratory disease including chronic lung disease, Trisomy 21, significant neurological disease including history of seizure disorder, significant impairment/alteration of the immune system including congenital immunodeficiency or any other disorder considered relevant by a medically qualified investigator
- Requiring admission to intensive care unit at enrolment
- Clinical suspicion of illness other than bronchiolitis
- Contraindication to the study drug or placebo (hypersensitivity), medical treatment with medication which in the opinion of the admitting team would make the child unsuitable for the study
- Receipt of investigational drug/vaccine, other than the drugs used in the study within 30 days prior to receiving the first dose of NTZ or their planned use during the study period until 1 month after the administration of the final dose of NTZ
- Previously enrolled in the study
- Parent less than 18 years of age
TEMPORARY EXCLUSION CRITERIA
- Receipt of an anti-viral medication within the previous 7 days
- Inability to tolerate either the oral or nasogastric route (e.g. ileus)
- Any systemic corticosteroid (or equivalent) treatment in 14 days prior to enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nitazoxanide
Nitazoxanide 7.5mg/kg oral/nasogastric/nasoenteric tube three times per day for five days.
|
Other Names:
|
Placebo Comparator: Placebo
The placebo is identical to the active drug described above except that it does not contain the active compound nitazoxanide.
It is reconstitutes, administered and dosed as per the active study drug.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity of respiratory distress
Time Frame: Up to day 4
|
The calculation of a Respiratory Assessment Change Score (RACS) by the use of the Respiratory Distress Assessment Instrument (RDAI) from baseline (day 1) to study day 4 adjusted for the standardised change in respiratory rate with points being assigned by change increments of 10% Internal reliability and responsiveness of the RACS as a measure of respiratory distress in infants has been previously demonstrated and it correlates well with other measures of respiratory distress
|
Up to day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasopharyngeal excretion of Respiratory Syncytial Virus (RSV)
Time Frame: Up to 72 hours
|
The change in nasopharyngeal viral excretion as measured by Polymerase Chain Reaction (PCR)
|
Up to 72 hours
|
Duration of parent reported solicited symptoms associated with bronchiolitis during and after treatment
Time Frame: Up to day 7
|
The time until the severity of ALL solicited symptoms associated with bronchiolitis (loss of appetite, activity level, respiratory effort and irritability) have first been assessed as mild or normal from the day of randomisation to the end of study day 7
|
Up to day 7
|
Actual duration of hospital admission for any reason
Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 1 to 3 days.
|
The period of time for which hospitalisation is required for any medical reason
|
Participants will be followed for the duration of hospital stay, an expected average of 1 to 3 days.
|
Need for interventional supportive medical care
Time Frame: Up to day 7
|
The use of oxygen therapy, supportive ventilation, admission to the Intensive Care Unit (ICU) and supportive hydration therapy (NG or IV).
Duration of use is calculated from the calendar day of randomisation to the date of cessation
|
Up to day 7
|
Severity of parent reported solicited symptoms associated with bronchiolitis during and after treatment
Time Frame: Up to day 7
|
The time until the severity of ALL solicited symptoms associated with bronchiolitis (loss of appetite, activity level, respiratory effort and irritability) have first been assessed as mild or normal from the day of randomisation to the end of study day 7
|
Up to day 7
|
Duration of interventional supportive medical care
Time Frame: Up to day 7
|
The use of oxygen therapy, supportive ventilation, admission to the Intensive Care Unit (ICU) and supportive hydration therapy (NG or IV).
Duration of use is calculated from the calendar day of randomisation to the date of cessation
|
Up to day 7
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of adverse events attributed to the study treatment
Time Frame: Participants will be followed for the duration of enrolment and up to 180 days post completion
|
The occurrence of adverse events attributed to the study treatment
|
Participants will be followed for the duration of enrolment and up to 180 days post completion
|
Recurrent bronchiolitis requiring health care assessment and /or intervention
Time Frame: Within 6 months of enrolment
|
Recurrent bronchiolitis requiring health care assessment and/or intervention
|
Within 6 months of enrolment
|
Prolongation of bronchiolitis
Time Frame: Up to 180 days post completion
|
Prolongation of bronchiolitis beyond day 7 after enrolment
|
Up to 180 days post completion
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Claire WADDINGTON, BMBS MSc MRCP (UK) DPhil, Telethon Kids Institute
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CVID/2014-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchiolitis
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedBronchiolitis Obliterans | Graft vs Host Disease | Constrictive Bronchiolitis | Bronchiolitis, Exudative | Bronchiolitis, ProliferativeUnited States
-
Hillel Yaffe Medical CenterCompletedReflexology | Bronchiolitis; ChemicalIsrael
-
Guy's and St Thomas' NHS Foundation TrustCompletedAcute Viral BronchiolitisUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisCompletedAcute Viral BronchiolitisFrance
-
Ministry of Health, SpainCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedBronchiolitis Obliterans | Graft Versus Host Disease | Graft-Versus-Host Disease | Constructive Bronchiolitis | Bronchiolitis, Exudative | Bronchiolitis, ProliferativeUnited States
-
Hospices Civils de LyonRecruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSevere Viral BronchiolitisFrance
-
University Hospital, Basel, SwitzerlandRecruitingBronchiolitis Obliterans Syndrome (BOS) | Bronchiolitis Obliterans (BO)Switzerland, Saudi Arabia
-
Groupe Hospitalier du HavreCompletedAcute Viral BronchiolitisFrance
Clinical Trials on Nitazoxanide
-
Azidus BrasilFarmoquimica S.A.; Hospital Vera Cruz; Hospital Casa de Saúde - Vera Cruz - Campinas... and other collaboratorsCompleted
-
Romark Laboratories L.C.CompletedRotavirus Infection | Norovirus Infection | Adenoviridae Infection
-
Azidus BrasilFarmoquimica S.A.Recruiting
-
Pinnacle Clinical Research, PLLCCompletedFatty Liver | Fibrosis, Liver | Compensated Cirrhosis | Non-alcoholic SteatohepatitisUnited States
-
Romark Laboratories L.C.CompletedRhinovirus | EnterovirusUnited States, Puerto Rico
-
Maha TalaabCompleted
-
Materno-Perinatal Hospital of the State of MexicoLaboratorios LiomontCompletedCoronavirus InfectionMexico
-
International Centre for Diarrhoeal Disease Research...University of VirginiaCompleted
-
Sadat City UniversityRecruitingIrritable Bowel Syndrome With DiarrheaEgypt
-
Coordinación de Investigación en Salud, MexicoUniversity College, London; Centro de Investigacion y Estudios Avanzados del... and other collaboratorsCompleted